Nanosized Drug Loaded Dispersion System Using Novel Isolated Biomaterial as Drug Release Modifier. It’s Development, Characterization and Release study

Epilepsy is a chronic brain illness that manifests as seizures, which are episodes of abnormal electrical activity in the brain. This study aimed to create the model drug-PHT-loaded bionanodispersion, reduce the long-term treatment expenses for epilepsy, and enhance therapeutic efficacy by utilizing the novel bioretardant from Juglans regia (JR). In order to create a nanocapsulated dispersion system, a new bioretardant with exceptional inherent characteristics was extracted. For the planning of details PLBND1 through PLBND5, various ratios of the bioretardant and the model drug, PHT, were used: 1:2, 1:3, 1:4, 1:5, and 1:8. Dispersibility, pH, % entrapment efficiency, stability studies, and in vitro drug discharge were evaluated for the bionanodispersion. With a t50% of 17.21 hours and an estimated r2 of 0.9974, the formulation PLBND2 with a 1:4 drug bioretardant proportion demonstrated noteworthy results for a number of evaluations. In 36 hours, PLBND2 demonstrated a steady drug delivery rate of 93.17% ± 1.8. Using a bioretardant with a remarkable stabilizing and retardant property, the bionanodispersion was proven to be safe and stable for the administration of the nanosized model drug, PHT.